List of Next-Gen Sequencing Companies in Sweden - 7

2A Pharma is a clinical stage Swedish/Danish biopharmaceuticals company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented vaccine platform. Our lead vaccine candidate, 2AP01, is a HPV (human papillomavirus) vaccine formulated without adjuvant. We believe 2AP01 will offer significant advantages over existing vaccines including broader protection against more HPV types and lower production cost. Our vaccine technology is based on adeno-associated virus-like particles (AAVLPs), that assemble viral capsids without containing viral genomes; hence they are replicative-defective and non-pathogenic. The viral capsid has repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, generating an immune response where both the innate and the adaptive immune system are activated. In other words, 2A Pharma exploit the efficacy of the individuals’ own immune system to generate AAVLP-based vaccines that, without the addition of adjuvants, are able to develop highly effective antibodies with selected specificities and functions. The technology enables the production of highly efficient vaccines with significant competitive advantages

Developing state-of-the-art AAV vectors for gene therapy

SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.

Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features do not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user – but also enable new and simplified workflows as well as novel laboratory protocols including heat cycles. Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition. Find out more at www.sequrna.com or email us at info@sequrna.com

SINGLE TECHNOLOGIES develops a new type of single molecule sensitive 3D sequencing system.

At TATAA Biocenter, we offer PCR bioanalytical services to address the challenges in nucleic acid therapy drug development. Our mission as a CRO is to provide assay development, validation, and high-throughput analyses with high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments to accelerate your time-to-market. As your extended workbench of specialists and dedicated partner, we prioritize quality, innovation, and building strong client relationships. We are a GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified laboratory. Our purpose-built facility for nucleic acid analyses enhances sensitivity and minimizes contamination risks. With state-of-the-art instrumentation and an IT structure ensuring the highest data integrity and sample management, our collaborative and highly skilled scientists deliver advanced competence and precise execution.

Single-cell and Bulk RNA-sequencing services.